Cell Free DNA accurately correlates with breast cancer DNA

Howard B. Urnovitz, Modulation of breast cancer cell-free DNA with surgical resection. J Clin Oncol 31, 2013 (suppl; abstr 11060)

Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center announced results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients at the American Society of Clinical Oncology Annual Meeting (ASCO 2013).

By | July 3rd, 2016|Other publications|0 Comments

Detection of novel HPV mutations and chromosomal number imbalance

Newswise

Newswise — CHICAGO (May 30, 2014) – Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral...

By | June 1st, 2016|Other publications|0 Comments

Clinica Highlights Chronix Biomedical’s Diagnostics

Tina Tan, Chronix’s new liquid biopsy approach show promise as early predictor of cancer therapies. Clinica, 18 April 2016.

A blood-based test which looks at chromosomal gains and losses in cell-free DNA (cfDNA) has demonstrated its potential of being a predictor of how well cancer patients are responding to chemotherapy.

By | April 18th, 2016|Other publications|0 Comments